EMA Withdrawn: Inpremzia (insulin human (rDNA)) — Baxter Holding B.V.

View source ↗

Summary

EMA has withdrawn Inpremzia, an insulin human (rDNA) product, from the market in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Inpremzia (insulin human (rDNA))

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus. MAH: Baxter Holding B.V.. Decision date: 04/04/2023